[1] https://www.wcrf.org/dietandcancer/cancer-trends/pancreatic-cancer-statistics
[2] https://www.uicc.org/news/new-global-cancer-data-globocan-2018
[3] Cancer Registry and Statics. Cancer Information Service, National Cancer Center, Japan.
[4] Biankin AV, Waddell N, Kassahn KS, et al: Pancreatic cancer genomes reveal aberrations in axon guidance pathway genes. Nature 2012; 491: 399- 405.
[5] Makohon-Moore A, Iacobuzio-Donahue CA: Pancreatic cancer biology and genetics from an evolutionary perspective. Nat Rev Cancer 2016; 16: 553-65.
[6] Kondo T, Kanai M, Kou T, et al: Association between homologous recombination repair gene mutations and response to oxaliplatin in pancreatic cancer. Oncotarget 2018; 9: 19817-25.
[7] Singh RR, Goldberg J, Varghese AM, et al: Genomic profiling in pancreatic ductal adenocarcinoma and a pathway towards therapy individualization: A scoping review. Cancer Treat Rev 2019; 75: 27-38.
[8] Hermann PC, Sainz B: Pancreatic cancer stem cells: A state or an entity? Semin Cancer Biol 2018; 53: 223-31.
[9] Li C, Heidt DG, Dalerba P, et al: Identification of pancreatic cancer stem cells. Cancer Res 2007; 67: 1030-7.
[10] Hermann PC, Huber SL, Herrler T, et al: Distinct populations of cancer stem cells determine tumor growth and metastatic activity in human pancreatic cancer. Cell Stem Cell 2007; 1: 313-23.
[11] Lin M, Sutherland DR, Horsfall W, et al: Cell surface antigen CD109 is a novel member of the alpha(2) macroglobulin/C3, C4, C5 family of thioester-containing proteins. Blood 2002; 99: 1683-91.
[12] Hashimoto M, Ichihara M, Watanabe T, et al: Expression of CD109 in human cancer. Oncogene 2004; 23: 3716-20.
[13] Qi R, Dong F, Liu Q, et al: CD109 and squamous cell carcinoma. J Transl Med 2018; 16: 88.
[14] Haun RS, Fan CY, Mackintosh SG, et al: CD109 overexpression in pancreatic cancer identified by cell-surface glycoprotein capture. J Proteomics Bioinform 2014; Suppl 10: S10003.
[15] Zong G, Xu Z, Zhang S, et al: CD109 mediates cell survival in hepatocellular carcinoma cells. Dig Dis Sci 2016; 61: 2303-14.
[16] Silver DJ, Lathia JD: Revealing the glioma cancer stem cell interactome, one niche at a time. J Pathol 2018; 244: 260-4.
[17] Hagiwara S, Murakumo Y, Sato T, et al: Up-regulation of CD109 expression is associated with carcinogenesis of the squamous epithelium of the oral cavity. Cancer Sci 2008; 99: 1916-1923.
[18] Emori M, Tsukahara T, Murase M, et al: High expression of CD109 antigen regulates the phenotype of cancer stem-like cells/cancer-initiating cells in the novel epithelioid sarcoma cell line ESX and is related to poor prognosis of soft tissue sarcoma. PLoS One 2013; 8: e84187.
[19] Emori M, Tsukahara T, Murata K, et al: Prognostic impact of CD109 expression in myxofibrosarcoma. J Surg Oncol 2015; 111: 975-9.
[20] Minata M, Audia A, Shi J, et al: Phenotypic plasticity of invasive edge glioma stem-like cells in response to ionizing radiation. Cell Rep 2019; 26: 1893-1905.e7.
[21] Finnson KW, Tam BY, Liu K, et al: Identification of CD109 as part of the TGF-beta receptor system in human keratinocytes. FASEB J 2006; 20: 1525-7.
[22] Bizet AA, Tran-Khanh N, Saksena A, et al: CD109-mediated degradation of TGF-β receptors and inhibition of TGF-β responses involve regulation of SMAD7 and smurf2 localization and function. J Cell Biochem 2012; 113: 238-46.
[23] Hagiwara S, Murakumo Y, Mii S, et al: Processing of CD109 by furin and its role in the regulation of TGF-beta signaling. Oncogene 2010; 29: 2181- 91.
[24] Morrison CD, Parvani JG, Schiemann WP: The relevance of the TGF-β paradox to EMT-MET programs. Cancer Lett 2013; 341: 30-40.
[25] Yeh HW, Lee SS, Chang CY, et al: A new switch for TGFβ in cancer. Cancer Res 2019; 79: 3797-805.
[26] David CJ, Huang YH, Chen M, et al: TGF-β tumor suppression through a lethal EMT. Cell 2016; 164: 1015-30.
[27] Shen W, Tao GQ, Zhang Y, et al: TGF-β in pancreatic cancer initiation and progression: Two sides of the same coin. Cell Biosci 2017; 7: 39.
[28] Alvarez MA, Freitas JP, Mazher Hussain S, et al: TGF-β inhibitors in metastatic pancreatic ductal adenocarcinoma. J Gastrointest Cancer 2019; 50: 207-13.
[29] Chuang CH, Greenside PG, Rogers ZN, et al: Molecular definition of a metastatic lung cancer state reveals a targetable cd109-janus kinase-stat axis. Nat Med 2017; 23: 291-300.
[30] Zhang JM, Murakumo Y, Hagiwara S, et al: CD109 attenuates TGF-β1 signaling and enhances EGF signaling in SK-MG-1 human glioblastoma cells. Biochem Biophys Res Commun 2015; 459: 252-8.
[31] Sunagawa M, Mii S, Enomoto A, et al: Suppression of skin tumorigenesis in CD109-deficient mice. Oncotarget 2016; 7: 82836-82850.
[32] Shiraki Y, Mii S, Enomoto A, et al: Significance of perivascular tumor cells defined by CD109 expression in progression of glioma. J Pathol 2017; 243: 468-480.
[33] Tao J, Li H, Li Q, et al: CD109 is a potential target for triple- negative breast cancer. Tumour Biol 2014; 35: 12083-90.